Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31234
Abstract: Tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with gastrointestinal stromal tumors (GISTs), but most patients eventually develop resistance and progress. Dasatinib is a potent inhibitor of BCR‐ABL, KIT, and SRC family kinases… read more here.
Keywords: term outcome; long term; dasatinib; gastrointestinal stromal ... See more keywords
Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31682
Abstract: Dasatinib is a potent second-generation tyrosine kinase inhibitor (TKI) that is used in the treatment of patients with chronic myeloid leukemia (CML), both in the upfront and salvage settings. After the Dasatinib Versus Imatinib Study… read more here.
Keywords: daily dose; treatment; dasatinib; therapy ... See more keywords
Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1416
Abstract: Despite clinical advances with protein kinase inhibitors (PKIs), oral administration of many PKIs is associated with highly variable plasma exposure and a narrow therapeutic window. We developed a novel hybrid nanoparticle‐amorphous solid dispersion (ASD) technology… read more here.
Keywords: technology; sorafenib; dasatinib; variability ... See more keywords
Dasatinib protects against acute respiratory distress syndrome via Nrf2-regulated M2 macrophages polarization.
Sign Up to like & getrecommendations! Published in 2021 at "Drug development research"
DOI: 10.1002/ddr.21839
Abstract: Dasatinib, a tyrosine kinase inhibitor, has a protective effect on experimental acute respiratory distress syndrome (ARDS). This study investigated the effect and mechanism of dasatinib in ARDS. C57BL/6 mice were administered with dasatinib (1 and… read more here.
Keywords: distress syndrome; dasatinib; effect; acute respiratory ... See more keywords
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3749-7
Abstract: ObjectiveTo determine the extent of dasatinib uptake and effect on Src kinase activity in tumor, normal adjacent tissue, and blood in newly diagnosed endometrial cancer patients.MethodsDasatinib was dosed at 100 or 200 mg PO BID at… read more here.
Keywords: newly diagnosed; dasatinib; tissue; diagnosed endometrial ... See more keywords
Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03962-8
Abstract: Triple-negative breast cancer (TNBC) has a poor prognosis because of limited treatment options. The combination of a poly ADP ribose polymerase (PARP) inhibitor with a DNA-damaging agent has shown promise in treating TNBC; however, not… read more here.
Keywords: combination; plus carboplatin; dasatinib; veliparib ... See more keywords
Dasatinib-induced chylothorax: report of a case and review of the literature
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-00932-3
Abstract: Dasatinib is a tyrosine kinase inhibitor for the treatment of BCR-ABL-positive chronic myeloid leukaemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL). Although fluid retention is a common adverse event associated with dasatinib, chylothorax is… read more here.
Keywords: dasatinib induced; chylothorax; dasatinib; case ... See more keywords
Dasatinib protects humanized mice from acute HIV-1 infection.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical pharmacology"
DOI: 10.1016/j.bcp.2019.113625
Abstract: HIV-1 infection remains incurable despite the efficient combined antiretroviral therapy (cART) due to the formation of long-lived viral reservoirs that are mostly settled in CD4+ T cells and maintained by homeostatic proliferation. The use of… read more here.
Keywords: hiv infection; infection; dasatinib; dasatinib protects ... See more keywords
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.05.013
Abstract: PURPOSE Oncogenic KRAS mutations occur frequently in solid tumours, but no clinically applicable targeted strategy is yet available for treating human cancers with mutant KRAS. Here we aimed to identify a strategy for the treatment… read more here.
Keywords: inhibitor; kinase; taz; dasatinib ... See more keywords
A validated UPLC–MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Pharmaceutical Analysis"
DOI: 10.1016/j.jpha.2017.07.009
Abstract: A sensitive, rapid, simple and economical ultra-performance liquid chromatography–tandem mass spectrometric method (UPLC–MS/MS) was developed and validated for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma using gliquidone as internal standard (IS). Liquid-liquid… read more here.
Keywords: simultaneous determination; human plasma; dasatinib; method ... See more keywords
Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Cell death discovery"
DOI: 10.1038/s41420-020-0270-7
Abstract: Proto-oncogene tyrosine-protein kinase Src plays an important role in Head and Neck Squamous Cell Carcinoma (HNSCC). However, the FDA-approved SRC inhibitor Dasatinib shows very limited efficacy in HNSCC clinical trials, even though Dasatinib can completely… read more here.
Keywords: cisplatin resistant; dasatinib; hnscc; ikk ... See more keywords